Although angiogenic activity is primarily controlled by the VEGF/VEGF-receptor system in adipose and tumor tissues, the biological mechanism by which orlistat reduces angiogenic capacity needs to be elucidated in future studies. This evidence concerns the gene VEGFA and neoplasm.